Contact
Please use this form to send email to PR contact of this press release:
Strong Q4 Results and Milestones Announced Including Approved Stock Dividend & 8 Million More in Capital: (Nasdaq: NRXP)
TO:
Matthew Duffy, Chief Business Officer
NRx Pharmaceuticals, Inc.
+1 484-254-6134